LNTH Lantheus |
$51.87
-28.6% |
-37.1%
 |
Piflufolastat F 18 (formerly 8F-DCFPyL)
Biochemically Recurrent Prostate Cancer (CONDOR)
|
NDA
Target date: March 06, 2026
|
8/6/2025 - PDUFA Date
Lantheus Holdings, announced that The FDA has set an action date goal of March 6, 2026 under the Pr…
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$105.93
-6.4% |
-2.9%
 |
dordaviprone
treatment for recurrent H3 K27M-mutant diffuse glioma
|
|
8/6/2025 - FDA GRANT
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted acc…
Full Summary
|
TEVA Teva Pharmaceutical Industries |
$16.05
+2.1% |
-3.6%
 |
AJOVY (Fremanezumab-vfrm)
Comorbid depression, anxiety or hypertension, as well as migraine
|
|
8/6/2025 - FDA approved
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S…
Full Summary
|
KROS Keros Therapeutics |
$14.41
+0.1% |
+3.6%
 |
KER-065
To treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins
|
|
8/6/2025 - Provided Update
Keros Therapeutics, Inc. announced a strategic realignment designed to reallocate resources towards…
Full Summary
|
LNTH Lantheus |
$51.87
-28.6% |
-37.1%
|
Piflufolastat F 18 (formerly 8F-DCFPyL)
Biochemically Recurrent Prostate Cancer (CONDOR)
|
NDA
|
8/6/2025 - FDA Accepted
Lantheus Holdings, announced that the Food and Drug Administration (FDA) has accepted a New Drug App…
Full Summary
|
MBRX Moleculin Biotech |
$0.66
-4.2% |
+25.8%
 |
Annamycin
Soft tissue sarcoma (STS) lung metastases
|
|
8/6/2025 - Presentation
Moleculin Biotech, Inc., announced the presentation of encouraging preclinical data for its lead dr…
Full Summary
|
BTAI BioXcel Therapeutics |
$3.32
+11.8% |
+65.2%
 |
BXCL501 (dexmedetomidine)
For dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist
|
|
8/6/2025 - Publication
BioXcel Therapeutics announced a publication in the peer-reviewed journal Frontiers in Pharmacology…
Full Summary
|
CING Cingulate |
$4.52
-16.6% |
+0.2%
 |
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
|
|
8/6/2025 - NDA Filing
Cingulate announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug …
Full Summary
|
LTRN Lantern Pharma |
$5.14
-1.2% |
+45.2%
 |
LP-184
Prostate cancer
|
IND
|
8/6/2025 - FDA Clearance
Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. announced that the U.S. Fo…
Full Summary
|
ACTU Actuate Therapeutics |
$8.17
+11.8% |
+30.9%
 |
elraglusib
In relapsed/refractory Ewing Sarcoma (r/r EWS).
|
Phase 1b
|
8/6/2025 - Trial Initiation
Actuate Therapeutics, Inc. announced the initiation of the Phase 1b trial of elraglusib in combinati…
Full Summary
|
CMRX Chimerix |
$8.54
|
|
dordaviprone
treatment for recurrent H3 K27M-mutant diffuse glioma
|
|
8/6/2025 - FDA GRANT
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted acc…
Full Summary
|
RNXT RenovoRx |
$1.20
-1.6% |
-7.7%
 |
RenovoCath
Solid Tumors
|
|
8/6/2025 - Provided Update
RenovoRx, Inc. announced strong progress in its commercialization efforts, including its growing cus…
Full Summary
|
DTIL Precision BioSciences |
$4.81
-1.0% |
+6.4%
 |
PBGENE-HBV
For chronic hepatitis B virus (HBV)
|
|
8/6/2025 - Results
Precision BioSciences, Inc announced ELIMINATE-B results as of the data cutoff of July 28, 2025.
Full Summary
|
MAT Mattel |
$17.30
+1.8% |
-13.9%
 |
Barbie
type 1 diabetes (T1D)
|
|
8/6/2025 - Provided Update
Mattel, Inc announced a partnership between its iconic Barbie™ brand and Quo Beauty®, the beloved an…
Full Summary
|
IMMX Immix Biopharma |
$2.60
-8.8% |
-2.3%
 |
NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.
|
|
8/6/2025 - Provided Update
Immix Biopharma, Inc. announced important updates about its plan to address other serious diseases…
Full Summary
|
URGN Urogen Pharma |
$20.01
-3.4% |
+46.0%
 |
ZUSDURI
for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
|
|
8/5/2025 - Provided Update
UroGen Pharma announced the 24-month DOR of 72.2% (95% CI 64.1%, 78.8%) by Kaplan-Meier estimate in…
Full Summary
|
IMMP Prima BioMed |
$1.75
-1.7% |
+2.9%
 |
eftilagimod alpha
For cancer and autoimmune disease
|
|
8/5/2025 - Positive Feedback
Immutep Limited announces it has received positive and constructive feedback from the US Food and D…
Full Summary
|
NUVB Nuvation Bio |
$2.35
-1.0% |
+14.5%
 |
IBTROZI
In Advanced ROS1-Positive Non-Small Cell Lung Cancer
|
|
8/5/2025 - Data Presentation
Nuvation Bio Inc announced that new data will be presented at the IASLC 2025 World Conference on Lun…
Full Summary
|
SAVA Cassava Sciences |
$2.34
-4.1% |
+12.5%
 |
Simufilam
Alzheimer's Disease
|
|
8/4/2025 - Positive Results
Cassava Sciences, Inc. today reported positive preclinical results of a study evaluating simufilam i…
Full Summary
|
DYN Dyne Therapeutics |
$11.59
+10.7% |
+38.1%
 |
DYNE-251
Duchenne Muscular Dystrophy
|
BLA
|
8/4/2025 - BLA Filing
Dyne Therapeutics, Inc announced that potential BLA submission for U.S. accelerated approval anticip…
Full Summary
|
DYN Dyne Therapeutics |
$11.59
+10.7% |
+38.1%
|
DYNE-251
Duchenne Muscular Dystrophy
|
Breakthrough Therapy
|
8/4/2025 - Designation Grant
Dyne Therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthr…
Full Summary
|
INMB INmune Bio |
$2.76
+2.6% |
+20.0%
 |
INKmune
High-Risk Myelodysplastic Syndrome (MDS)
|
Phase 1/2
|
8/4/2025 - Provided Update
INmune Bio Inc. is pleased to report that its Phase I/II trial (the "CaRe PC" trial) of INKmune™ fo…
Full Summary
|
TMDX TransMedics Group |
$118.80
-5.5% |
-4.8%
 |
OCS™ Heart System
For patients with end-stage lung, heart, and liver failure
|
Investigational Device Exemption
|
8/4/2025 - Conditional approval
TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted cond…
Full Summary
|
DYN Dyne Therapeutics |
$11.59
+10.7% |
+38.1%
|
DYNE-251
Duchenne Muscular Dystrophy
|
Target date: LATE 2025
|
8/4/2025 - Data Presentation
Dyne Therapeutics, Inc. announced that Data from the DELIVER registrational expansion cohort is exp…
Full Summary
|
CASI CASI Pharmaceuticals |
$1.68
-13.4% |
+19.6%
 |
CID-103
Relapsed Or Refractory Multiple Myeloma
|
|
8/4/2025 - FDA Clearance
CASI Pharmaceuticals, Inc. announced FDA clearance of an IND application for CID-103, an anti-CD38…
Full Summary
|
VRTX Vertex Pharmaceuticals |
$385.65
+2.8% |
-17.3%
 |
VX-993
For the Treatment of Acute Pain
|
Phase 2
|
8/4/2025 - Top-line results
Vertex Pharmaceuticals Incorporated announced topline results from its recently completed Phase 2,…
Full Summary
|
BMY Bristol Myers Squibb |
$44.82
-2.2% |
-4.8%
 |
Breyanzi (lisocabtagene maraleucel)
Second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL)
|
sBLA
|
8/4/2025 - Application Accepted
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the sup…
Full Summary
|
SAVA Cassava Sciences |
$2.34
-4.1% |
+12.5%
|
Simufilam
Alzheimer's Disease
|
Target date: H1 2026
|
8/4/2025 - Clinical Study
Cassava Sciences, Inc. announced that First clinical study for simufilam in TSC-related epilepsy ex…
Full Summary
|
BMY Bristol Myers Squibb |
$44.82
-2.2% |
-4.8%
|
Breyanzi (lisocabtagene maraleucel)
Second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL)
|
sBLA
Target date: December 05, 2025
|
8/4/2025 - PDUFA Date
Bristol Myers Squibb announced that The FDA has granted the application Priority Review and assign…
Full Summary
|
XCUR Exicure |
$7.69
+3.9% |
+10.6%
 |
burixafor
In Multiple Myeloma
|
Target date: Q4 2025
|
8/1/2025 - Top-line results
Exicure, Inc. announced that the Topline results from the study are expected in the fourth quarter …
Full Summary
|
BTAI BioXcel Therapeutics |
$3.32
+11.8% |
+65.2%
|
IGALMI™
Sublingual film
|
Phase 3
|
8/1/2025 - Pivotal Study
BioXcel Therapeutics, announced completion of the last patient last visit (LPLV) in the pivotal Phas…
Full Summary
|
VTRS Viatris |
$8.75
-2.6% |
-5.5%
 |
meloxicam
For the Treatment of Moderate-to-Severe Acute Pain
|
Phase 3
|
8/1/2025 - Abstract
Viatris announced that five abstracts from its Phase 3 program evaluating novel fast-acting formula…
Full Summary
|
XCUR Exicure |
$7.69
+3.9% |
+10.6%
|
burixafor
In Multiple Myeloma
|
Phase 2
|
8/1/2025 - Provided Update
Exicure, Inc announced it has completed the last patient, last visit in its ongoing Phase 2 clinical…
Full Summary
|
ALLO Allogene Therapeutics |
$1.06
-5.4% |
-11.7%
 |
Cemacabtagene Ansegedleucel
For Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
|
|
8/1/2025 - Provided Update
Allogene Therapeutics, Inc announced that it has selected standard fludarabine and cyclophosphamide…
Full Summary
|
AVXL Anavex Life Sciences |
$10.97
+0.7% |
+7.7%
 |
ANAVEX®2-73-AD-EP-004
for the potential treatment of early Alzheimer's disease.
|
|
7/31/2025 - Findings Update
Anavex Life Sciences Corp announced the latest findings for blarcamesine, an oral small molecule fo…
Full Summary
|
LTRN Lantern Pharma |
$5.14
-1.2% |
+45.2%
|
RADR
AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs).
|
Phase 2
|
7/31/2025 - Enrollment Completion
Lantern Pharma Inc. ( announced the successful completion of targeted enrollment for its Phase 2 HAR…
Full Summary
|
NVCT Nuvectis Pharma |
$6.46
-6.4% |
-14.8%
 |
NXP800
To treat platinum resistant, ARID1a-mutated ovarian carcinoma.
|
Phase 1b
|
7/31/2025 - Clinical Update
Nuvectis Pharma, Inc. today provided the final clinical data update from the Phase 1b study of NXP8…
Full Summary
|
EOLS Evolus |
$6.37
-28.5% |
-31.2%
 |
Jeuveau
Aesthetics
|
|
7/31/2025 - Publication
Evolus, Inc. announced the publication of a landmark independent study in JAMA Dermatology directly…
Full Summary
|
FDMT 4D Molecular Therapeutics |
$5.73
-5.3% |
+35.8%
 |
4D-150
Intravitreal vector, R100, and a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi.
|
|
7/31/2025 - Positive Results
4D Molecular Therapeutics announced positive results from the SPECTRA clinical trial evaluating 4D-1…
Full Summary
|
LLY Eli Lilly and Company |
$746.17
-2.6% |
-4.1%
 |
tirzepatide
For obesity or overweight with weight-related comorbidities, excluding type 2 diabetes.
|
Phase 3
|
7/31/2025 - Top-line results
Eli Lilly Announced Topline Results From SURPASS-CVOT Head-to-head Phase 3 Trial Comparing Mounjaro …
Full Summary
|
TIL Instil Bio |
$26.31
-2.5% |
+12.3%
 |
IMM2510/AXN-2510
For front-line patients with advanced non-small cell lung cancer (NSCLC)
|
Phase 2
|
7/31/2025 - Efficacy and Safety Data
Instil Bio, Inc. announced preliminary safety and efficacy data from the Phase 2 open-label, multic…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$28.05
-3.0% |
-28.8%
 |
GTX-102 (PP)
Pediatric patients with Angelman syndrome in Canada
|
Phase 3
|
7/31/2025 - Enrollment Update
Ultragenyx Pharmaceutical announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) …
Full Summary
|
BGNE BeiGene |
|
|
BGB-16673
For adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
|
PRIority MEdicines (PRIME) designation
|
7/31/2025 - Designation Grant
BeOne Medicines announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.43
-6.5% |
+26.5%
 |
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
|
7/30/2025 - Preclinical Data
MIRA Pharmaceuticals, announced new preclinical data showing that its topical Ketamir-2 cream delive…
Full Summary
|
SNY Sanofi |
$46.18
-3.5% |
-4.2%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
Phase 1/2
|
7/30/2025 - Clinical Data
Sensei Biotherapeutics, Inc that clinical data from the dose expansion cohort of the Phase 1/2 trial…
Full Summary
|
BVS Bioventus |
$7.29
+18.7% |
|
TalisMann
For chronic pain management.
|
|
7/30/2025 - Provided Update
Bioventus Inc announced today a significant milestone with the U.S. Food and Drug Administration (FD…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$555.13
-2.6% |
+1.3%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
Phase 1/2
|
7/30/2025 - Clinical Data
Sensei Biotherapeutics, Inc that clinical data from the dose expansion cohort of the Phase 1/2 trial…
Full Summary
|
ABBV AbbVie |
$196.37
-1.1% |
+3.6%
 |
RINVOQ (upadacitinib)
Moderate to Severe Atopic Dermatitis
|
|
7/30/2025 - Top-line results
AbbVie announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA…
Full Summary
|
LLY Eli Lilly and Company |
$746.17
-2.6% |
-4.1%
|
donanemab-azbt
In early symptomatic Alzheimer's disease
|
Phase 3
|
7/30/2025 - Results
Eli Lilly and Company announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZ…
Full Summary
|
ANIK Anika Therapeutics |
$8.25
-1.2% |
-24.9%
 |
Hyalofast
Intended as support for the entrapment of mesenchymal stem cells obtained from autologous bone marrow aspirate concentrate (BMAC) for the repair of chondral and osteochondral lesions.
|
|
7/30/2025 - Top-line results
Anika Therapeutics, Inc. announced topline results from its U.S. pivotal clinical trial of Hyalofas…
Full Summary
|
CRBP Corbus Pharmaceuticals |
$9.11
+2.4% |
+20.8%
 |
CRB-701
Targets the expression of Nectin-4 on cancer cells
|
|
7/30/2025 - Abstract
Corbus Pharmaceuticals announced that an abstract on updated clinical data from its Phase 1/2 clini…
Full Summary
|
BDX Becton, Dickinson and Company |
$172.50
-2.5% |
-1.2%
 |
BD Veritor™ System
For SARS-CoV-2
|
|
7/30/2025 - FDA Clearance
BD (Becton, Dickinson and Company) announced that it has received U.S. Food and Drug Administration …
Full Summary
|
IXHL Incannex Healthcare |
$0.35
-15.2% |
+57.1%
 |
IHL-42X
Obstructive Sleep Apnoea (OSA)
|
|
7/30/2025 - Top-line results
Incannex Healthcare Inc is excited to share positive topline results from its RePOSA Phase 2 clinic…
Full Summary
|
BIIB Biogen |
$129.34
-2.7% |
-3.8%
 |
LEQEMBI® (lecanemab-irmb)
Treatment of Alzheimer's Disease
|
|
7/30/2025 - Results
Eisai Co., Ltd. and Biogen Inc announced that results on investigational maintenance therapy with…
Full Summary
|
TNYA Tenaya Therapeutics |
$0.67
-3.0% |
+6.6%
 |
TN-201
Fully functional MYBPC3 gene
|
|
7/30/2025 - Provided Update
Tenaya Therapeutics, Inc announced positive endorsements from each trial's independent Data Safety a…
Full Summary
|
NAMS NewAmsterdam Pharma |
$23.62
+8.7% |
+18.0%
 |
LDL-C
For Alzheimer's Disease
|
|
7/30/2025 - Data
NewAmsterdam Pharma Company N.V announced full data from the prespecified Alzheimer's disease ("AD")…
Full Summary
|
SGHT Sight Sciences |
$3.68
+5.4% |
+3.7%
 |
TearCare System
Meibomian Gland Dysfunction (MGD)
|
|
7/29/2025 - Results
Sight Sciences, Inc. announced that the manuscript detailing 24-month results from Stage 3 of the SA…
Full Summary
|
FULC Fulcrum Therapeutics |
$6.94
+0.9% |
-11.6%
 |
pociredir
In sickle cell disease
|
|
7/29/2025 - Positive Results
Fulcrum Therapeutics, today reported positive results from the 12 mg dose cohort of the Phase 1b PIO…
Full Summary
|
CGTX Cognition Therapeutics |
$0.71
-0.7% |
+20.8%
 |
CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.
|
Phase 2
|
7/29/2025 - Results
Cognition Therapeutics, presented results from the Phase 2 COG1201 SHIMMER study (NCT05225415) of z…
Full Summary
|
CING Cingulate |
$4.52
-16.6% |
+0.2%
|
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
|
NDA
|
7/29/2025 - Provided Update
Cingulate Inc. announced that it has received a fiscal year 2025 PDUFA (Prescription Drug User Fee A…
Full Summary
|
ATOS Atossa Genetics |
$0.79
-2.1% |
-7.0%
 |
endoxifen-Z
for Breast Cancer
|
|
7/29/2025 - Feedback
Atossa Therapeutics, Inc. announced positive written feedback from the U.S. Food and Drug Administr…
Full Summary
|
ONCY Oncolytics Biotech |
$0.93
-2.1% |
-25.6%
 |
Pelareorep
In Breast Cancer
|
|
7/29/2025 - Provided Update
Oncolytics Biotech® Inc. Assuming discussions with the FDA go as expected, the Company expects to c…
Full Summary
|
JNJ Johnson & Johnson |
$170.72
0.0% |
+9.6%
 |
Guselkumab
For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
|
sBLA
|
7/29/2025 - sBLA Filing
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) t…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.43
-6.5% |
+26.5%
|
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
IND
|
7/29/2025 - FDA Clearance
MIRA Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has cleared its Inv…
Full Summary
|
ACRS Aclaris Therapeutics |
$1.55
|
+6.9%
 |
ATI-2138
For the Treatment of Moderate to Severe Atopic Dermatitis
|
Phase 2a
|
7/29/2025 - Top-line results
Aclaris Therapeutics, Inc. announced positive top-line results from its open-label, single-arm Phas…
Full Summary
|
ABBV AbbVie |
$196.37
-1.1% |
+3.6%
|
venetoclax
For Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
|
supplemental New Drug Application (sNDA)
|
7/29/2025 - sNDA Filing
AbbVie announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and …
Full Summary
|
LLY Eli Lilly and Company |
$746.17
-2.6% |
-4.1%
|
Pirtobrutinib
A non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult
|
Phase 3
|
7/29/2025 - Top-line results
Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-314 clinical tr…
Full Summary
|
DARE Dare Bioscience |
$2.26
-5.8% |
-5.8%
 |
Sildenafil Cream
Women with Female Sexual Arousal Disorder
|
Phase 1
|
7/29/2025 - Provided Update
Daré Bioscience, Inc. announced the launch of the first phase of a consumer awareness campaign to s…
Full Summary
|
EYPT Eyepoint Pharmaceuticals |
$10.58
-2.8% |
+6.3%
 |
DURAVYU
In patients with non-proliferative diabetic retinopathy (NPDR).
|
Phase 3
|
7/29/2025 - Enrollment Update
EyePoint Pharmaceuticals, Inc. announced it has completed enrollment of its Phase 3 pivotal program…
Full Summary
|
ONCY Oncolytics Biotech |
$0.93
-2.1% |
-25.6%
|
Pelareorep
In Breast Cancer
|
|
7/29/2025 - Regulatory Update
Oncolytics Biotech® Inc announced it has initiated regulatory discussions with the U.S. Food and Dru…
Full Summary
|
HOTH Hoth Therapeutics |
$1.32
-4.3% |
+1.5%
 |
HT-001
Cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR
|
Phase 2
|
7/29/2025 - Clinical Trial
Hoth Therapeutics, Inc announced its engagement with ICON Clinical Research Limited ("ICON") to expa…
Full Summary
|
NKTR Nektar Therapeutics |
$22.45
-0.5% |
-1.2%
 |
Rezpegaldesleukin
For the treatment of atopic dermatitis.
|
Fast Track
|
7/29/2025 - Designation Grant
Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast T…
Full Summary
|
CRDF Cardiff Oncology |
$2.44
-5.1% |
-38.1%
 |
CRDF-004
RAS-mutated mCRC.
|
Phase 2
|
7/29/2025 - Positive Data
Cardiff Oncology, Inc. announced positive data from the ongoing CRDF-004, a randomized, Phase 2 clin…
Full Summary
|
ATHE Alterity Therapeutics |
$5.15
-4.6% |
+25.3%
 |
ATH434
To inhibit the aggregation of pathological proteins implicated in neurodegeneration
|
Phase 2
|
7/28/2025 - Top-line data
Alterity Therapeutics announced positive topline data from the ATH434-202 open-label Phase 2 clinica…
Full Summary
|
MRNA Moderna |
$26.71
-2.8% |
-17.9%
 |
mRNA-4359
Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma
|
|
7/28/2025 - Abstract
Moderna, Inc. announced that three abstracts on its investigational mRNA therapeutics have been acc…
Full Summary
|
URGN Urogen Pharma |
$20.01
-3.4% |
+46.0%
|
UGN-102
Low-grade, intermediate-risk, Non-muscle invasive bladder cancer (NMIBC)
|
Phase 3b
|
7/28/2025 - Publication
UroGen Pharma Ltd. announced the publication in Reviews in Urology of results from a Phase 3b study…
Full Summary
|
ENTX Entera Bio |
$1.98
-2.0% |
+11.2%
 |
EB613
Parathyroid hormone (1-34), or PTH for osteoporosis
|
Type A Meeting
|
7/28/2025 - Provided Update
Entera Bio Ltd. announced that in a written response to a Type A meeting request, the U.S. Food an…
Full Summary
|
ABOS Acumen Pharmaceuticals |
$1.40
+2.9% |
+15.7%
 |
Sabirnetug
for Early Alzheimer's Disease
|
|
7/28/2025 - Results
Acumen Pharmaceuticals, announced results showing that implementing a blood-based pTau217 screening…
Full Summary
|
ZYME Zymeworks |
$12.41
-1.0% |
-4.2%
 |
ZW251
In hepatocellular carcinoma models
|
NDA
|
7/28/2025 - FDA Clearance
Zymeworks announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new…
Full Summary
|
ASND Ascendis Pharma A/S |
$182.60
-2.1% |
+8.6%
 |
SKYTROFA®
For the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
|
|
7/28/2025 - FDA approved
Ascendis Pharma announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lo…
Full Summary
|
ENLV Enlivex Therapeutics |
$1.35
-2.9% |
+14.4%
 |
Allocetra
Sepsis
|
Phase 2
|
7/28/2025 - Provided Update
Enlivex Therapeutics Ltd announced that all 134 patients in its Phase II stage of its randomized, co…
Full Summary
|
RADX Radiopharm Theranostics |
$5.05
-3.8% |
+24.7%
 |
RV-01
For the 4Ig isoform
|
IND
|
7/28/2025 - FDA Clearance
Radiopharm Theranostics announced that the U.S. Food and Drug Administration (FDA) has provided cle…
Full Summary
|
AZN AstraZeneca |
$73.60
-1.2% |
+5.1%
 |
Durvalumab
Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy
|
sBLA Priority Review
|
7/28/2025 - FDA GRANT
AstraZeneca announced that supplemental Biologics License Application (sBLA) for Imfinzi (durvaluma…
Full Summary
|
IMMP Prima BioMed |
$1.75
-1.7% |
+2.9%
|
eftilagimod alpha
For cancer and autoimmune disease
|
|
7/28/2025 - Abstract
Immutep Limited announces three abstracts for clinical trials evaluating its first-in-class MHC Cla…
Full Summary
|
BGNE BeiGene |
|
|
TEVIMBRA
For the first-line treatment of patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
|
EMA
|
7/28/2025 - Positive Opinion
BeOne Medicines Ltd announced that the Committee for Medicinal Products for Human Use (CHMP) of the…
Full Summary
|
FULC Fulcrum Therapeutics |
$6.94
+0.9% |
-11.6%
|
pociredir
In sickle cell disease
|
|
7/28/2025 - Top-line results
Fulcrum Therapeutics to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER …
Full Summary
|
ATHE Alterity Therapeutics |
$5.15
-4.6% |
+25.3%
|
ATH434-202
In Multiple System Atrophy
|
|
7/28/2025 - Top-line data
Alterity Therapeutics announced positive topline data from the ATH434-202 open-label Phase 2 clinic…
Full Summary
|
PRQR ProQR Therapeutics |
$2.06
-2.8% |
-6.4%
 |
Axiomer
Editing Technology Adenosine Deaminase Acting on RNA)
|
|
7/28/2025 - Provided Update
ProQR Therapeutics NV announced that it will participate in the RNA Editing Summit taking place Jul…
Full Summary
|
RNA Avidity Biosciences |
$48.26
+26.1% |
+65.0%
 |
del-desiran
for Treatment of Myotonic Dystrophy Type 1
|
Target date: Q4 2025
|
7/28/2025 - Efficacy and Safety Data
Avidity Biosciences, Inc. announced that On track to share updates from ongoing MARINA-OLE™ trial of…
Full Summary
|
RNXT RenovoRx |
$1.20
-1.6% |
-7.7%
|
RenovoCath
Solid Tumors
|
|
7/28/2025 - Provided Update
RenovoRx, Inc. announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).
Full Summary
|
SRPT Sarepta Therapeutics |
$16.26
-2.9% |
-14.6%
 |
ELEVIDYS (delandistrogene moxeparvovec-rokl)
Designed to address the underlying cause of Duchenne muscular dystrophy through the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
|
|
7/28/2025 - FDA Notification
Sarepta Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) notified Sarep…
Full Summary
|
RNA Avidity Biosciences |
$48.26
+26.1% |
+65.0%
|
del-desiran
for Treatment of Myotonic Dystrophy Type 1
|
Phase 3
|
7/28/2025 - Enrollment Completion
Avidity Biosciences, Inc. announced the completion of enrollment in the ongoing global Phase 3 HARB…
Full Summary
|
RNA Avidity Biosciences |
$48.26
+26.1% |
+65.0%
|
del-desiran
for Treatment of Myotonic Dystrophy Type 1
|
Phase 3
Target date: Q2 2026
|
7/28/2025 - Top-line data
Avidity Biosciences, Inc. announced that Topline data from HARBOR, the first global Phase 3 clinical…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.43
-6.5% |
+26.5%
|
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
IND
|
7/28/2025 - FDA Clearance
MIRA Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared it…
Full Summary
|
CGEN Compugen |
$1.46
|
-14.1%
 |
COM701
Solid tumors
|
Phase 1
|
7/28/2025 - Data Presentation
Compugen Ltd. announced that it will present a pooled analysis of data from three Phase 1 trials eva…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$555.13
-2.6% |
+1.3%
|
Semaglutide (GLP-1 receptor agonist)
induced Weight Loss by Preserving Lean Mass
|
Phase 1b
|
7/28/2025 - Positive Results
Lexaria Bioscience Corp. provides the following partial 8-week positive interim results update on t…
Full Summary
|
CELC Celcuity |
$44.19
+3.2% |
+229.8%
 |
Gedatolisib
HR+ / HER2- Metastatic Breast Cancer
|
|
7/28/2025 - Top-line results
Celcuity Inc announced positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIK…
Full Summary
|
CELC Celcuity |
$44.19
+3.2% |
+229.8%
|
Gedatolisib
HR+ / HER2- Metastatic Breast Cancer
|
Phase 1b
|
7/28/2025 - Top-line results
Celcuity Inc reported topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 tri…
Full Summary
|
APLS Apellis Pharmaceuticals |
$23.73
-1.9% |
+32.6%
 |
pegcetacoplan
Paroxysmal nocturnal hemoglobinuria (PNH)
|
FDA Approved
|
7/28/2025 - FDA approved
Apellis Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has approved EM…
Full Summary
|
ASMB Assembly Biosciences |
$19.43
+3.0% |
+7.4%
 |
ABI-5366
For recurrent genital herpes.
|
Phase 1a
|
7/26/2025 - Poster Presentation
Assembly Biosciences, Inc announced Phase 1a clinical and preclinical data for its herpes simplex vi…
Full Summary
|
